Literature DB >> 22487055

Cationic liposomes as adjuvants for influenza hemagglutinin: more than charge alone.

Christophe Barnier Quer1, Abdelrahman Elsharkawy, Stefan Romeijn, Alexander Kros, Wim Jiskoot.   

Abstract

Cationic liposomes are known as potent adjuvants for subunit vaccines. The purpose of this work was to study whether the content and the physicochemical properties of the positively charged compound affect the adjuvanticity of cationic liposomes. Cationic liposomes containing a cationic compound (DDA, DPTAP, DC-Chol, or eDPPC) and a neutral phospholipid (DPPC) were prepared by the film hydration-extrusion method and loaded with influenza hemagglutinin (HA) by adsorption. The liposomes were characterized (hydrodynamic diameter, zeta potential, membrane fluidity, HA loading) and their adjuvanticity was tested in mice. The formulations were administered twice subcutaneously and mouse sera were analyzed for HA-specific antibodies by ELISA and for HA-neutralizing antibodies by hemagglutination inhibition (HI) assay. First, the influence of cationic lipid concentration in the DC-Chol/DPPC liposomes (10 vs. 50 mol%) was investigated. The DC-Chol/DPPC (50:50) liposomes showed a higher zeta potential and HA loading, resulting in stronger immunogenicity of the HA/DC-Chol/DPPC (50:50) liposomes compared to the corresponding (10:90) liposomes. Next, we used liposomes composed of 50 mol% cationic lipids to investigate the influence of the nature of the cationic compound on the adjuvant effect. Liposomes made of the four cationic compounds showed similar hydrodynamic diameters (between 100 and 170 nm), zeta potentials (between +40 and +50 mV), HA loading (between 55% and 76%) and melting temperatures (between 40 and 55 °C), except for the DC-Chol liposomes, which did not show any phase transition. HA adjuvanted with the DC-Chol/DPPC (50:50) liposomes elicited significantly higher total IgG1 and IgG2a titers compared to the other liposomal HA formulations and non-adjuvanted HA. A similar trend was observed for the HI titers. These results show that the adjuvanticity of cationic liposomes depends on both the content and the physicochemical properties of the charged compound.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22487055     DOI: 10.1016/j.ejpb.2012.03.013

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  10 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

Review 2.  Biomaterials for nanoparticle vaccine delivery systems.

Authors:  Preety Sahdev; Lukasz J Ochyl; James J Moon
Journal:  Pharm Res       Date:  2014-05-22       Impact factor: 4.200

3.  Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like Peptides.

Authors:  Faranak S Nouri; Xing Wang; Xuguang Chen; Arash Hatefi
Journal:  Pharm Res       Date:  2015-03-31       Impact factor: 4.200

4.  Long-term silencing of intersectin-1s in mouse lungs by repeated delivery of a specific siRNA via cationic liposomes. Evaluation of knockdown effects by electron microscopy.

Authors:  Cristina Bardita; Dan Predescu; Sanda Predescu
Journal:  J Vis Exp       Date:  2013-06-21       Impact factor: 1.355

5.  Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.

Authors:  Larry R Smith; Walter Wodal; Brian A Crowe; Astrid Kerschbaum; Peter Bruehl; Michael G Schwendinger; Helga Savidis-Dacho; Sean M Sullivan; Mark Shlapobersky; Jukka Hartikka; Alain Rolland; P Noel Barrett; Otfried Kistner
Journal:  Hum Vaccin Immunother       Date:  2013-03-06       Impact factor: 3.452

Review 6.  Cationic Nanoparticle-Based Cancer Vaccines.

Authors:  Jeroen Heuts; Wim Jiskoot; Ferry Ossendorp; Koen van der Maaden
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

7.  A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge.

Authors:  Zachary R Sia; Xuedan He; Ali Zhang; Jann C Ang; Shuai Shao; Amal Seffouh; Wei-Chiao Huang; Michael R D'Agostino; Amir Teimouri Dereshgi; Sambhara Suryaprakash; Joaquin Ortega; Hanne Andersen; Matthew S Miller; Bruce A Davidson; Jonathan F Lovell
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-01       Impact factor: 11.205

8.  The role of nanoliposome bilayer composition containing soluble leishmania antigen on maturation and activation of dendritic cells.

Authors:  Sara Shokooh Saremi; Maryam Shahryari; Razieh Ghoorchian; Hamed Eshaghian; Seyed Amir Jalali; Amin Reza Nikpoor; Mahmoud Reza Jafari; Ali Badiee
Journal:  Iran J Basic Med Sci       Date:  2018-05       Impact factor: 2.699

9.  Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators.

Authors:  Christophe Barnier-Quer; Abdelrahman Elsharkawy; Stefan Romeijn; Alexander Kros; Wim Jiskoot
Journal:  Pharmaceutics       Date:  2013-07-25       Impact factor: 6.321

10.  The Directional Observation of Highly Dynamic Membrane Tubule Formation Induced by Engulfed Liposomes.

Authors:  Xiaoming Zhang; Luru Dai; Anhe Wang; Christian Wölk; Bodo Dobner; Gerald Brezesinski; Yunqing Tang; Xianyou Wang; Junbai Li
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.